Human Immunology News 6.29 July 24, 2018 | |
| |
TOP STORYTIGIT+ iTregs Elicited by Human Regulatory Macrophages Control T Cell Immunity Investigators showed that human macrophages convert allogeneic CD4+ T cells to IL-10-producing, TIGIT+ FoxP3+-induced regulatory T cells (iTregs) that non-specifically suppress bystander T cells and inhibit dendritic cell maturation. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers identified monocyte-related CSF1R+Flt3– antigen presenting cells that constitute about half of the cells classically defined as SIRPα+ dendritic cells in the steady-state human small intestine. [Mucosal Immunol] Abstract Scientists performed two cross-sectional studies in antiparkinson drug-treated and drug-naïve Parkinson’s disease patients, and in age- and sex-matched healthy subjects. In the first one, they examined circulating Th1, Th2, Th17, and in the second one circulating Treg. [J Neuroinflammation] Full Article Using CRISPR/Cas9 knockout THP-1 cells lacking the human caspase-11 homologs, caspase-4 and -5, scientists demonstrated that caspase-5 but not caspase-4 is required for inflammasome activation by P. aeruginosa outer membrane vesicles in human monocytes. [Immunol Cell Biol] Abstract Cytokine Regulation in Human CD4 T Cells by the Aryl Hydrocarbon Receptor and Gq-Coupled Receptors Researchers studied the aryl hydrocarbon receptor (AhR)-dependent transcriptome in human CD4 T cells treated with Th17-inducing cytokines. They showed that the AhR reciprocally regulates IL-17 and IL-22 production in human CD4 T cells. [Sci Rep] Full Article Investigators characterized the effects of FTY720 on human T cell receptor (TCR) signaling pathways. FTY720 inhibited both the TCR-dependent and independent activation of primary human T cells. [Sci Rep] Full Article Scientists evaluated the changes in CD4 T-cell subsets throughout the entirety of infection and analyzed their relationships with disease severity in SFTS patients. In parallel with CD4 T-cell depletion, decreased Th1, Th2 and Treg numbers, but comparable Th17-cell numbers, were observed in deceased patients compared with those in surviving patients. [Clin Immunol] Abstract The authors investigated the effects of co-releasing proteases on the kinetics of release of the chemokine monocyte chemoattractant protein-1 in immunoglobulin E-mediated activation of human mast cells. [Int Arch Allergy Immunol] Abstract Defective BTLA Functionality Is Rescued by Restoring Lipid Metabolism in Lupus CD4+ T Cells Researchers investigated B and T lymphocyte attenuator (BTLA) expression on various T cell subsets, and they did not observe significant variations of BTLA expression between lupus patients and healthy controls. However, the enhancement of BTLA expression after activation was significantly lower in systemic lupus erythematosus patients compared with that in healthy controls. [JCI Insight] Full Article Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News. | |
| |
REVIEWSHistone Deacetylase Function in CD4+ T Cells The authors discuss studies revealing that histone deacetylases (HDACs) are key regulators of CD4+ T cell-mediated immunity in mice and humans and that HDACs are promising targets in T cell-mediated immune diseases. [Nat Rev Immunol] Abstract Visit our reviews page to see a complete list of reviews in the human immunology research field. | |
| |
INDUSTRY NEWSAvalon GloboCare Corp. announced that the company has formed a new wholly owned U.S. subsidiary, Avactis Biosciences, Inc., which will be focused on accelerating commercial activities related to its proprietary chimeric antigen receptor (CAR)-T technologies. [Avalon GloboCare Corp.] Press Release Mustang Bio Completes Pre-IND Meeting with FDA for MB-102 (CD123 CAR T) Mustang Bio, Inc. announced that it has completed a pre-Investigational New Drug (pre-IND) meeting with the FDA for MB-102. [Mustang Bio, Inc.] Press Release Sangamo Therapeutics to Acquire TxCell Sangamo Therapeutics, Inc. and TxCell S.A. announced that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the contemplated acquisition of a majority stake of TxCell, file a simplified cash tender offer for the purchase of all then outstanding ordinary shares of TxCell, at a price of €2.58 per share in cash, or approximately €72 million, on a debt-free and cash-free basis. [Sangamo Therapeutics, Inc.] Press Release | |
| |
POLICY NEWSNIH Delays Controversial Clinical Trials Policy for Some Studies Basic brain and behavioral researchers will get more than a year to comply with a new U.S. policy that will treat many of their studies as clinical trials. The announcement from the National Institutes of Health (NIH) appears to defuse, for now, a yearlong controversy over whether basic research on humans should follow the same rules as studies testing drugs. [ScienceInsider] Editorial University of Edinburgh Demands Retraction of Researcher’s Papers The University of Edinburgh has asked for the retraction of five papers by cell biologist and former faculty member Irina Stancheva following an internal investigation into scientific misconduct allegations, according to Times Higher Education. [The Scientist] Editorial Philippines Sweetens Deal for Scientists Who Return Home A renewed government effort to draw Filipino scientists back to the Philippines by paying them to set up their own research labs or teach has met with a mixed reception. [Nature News] Editorial
| |
EVENTSNEW Federation of American Societies for Experimental Biology (FASEB): Cross-Translational Research in Fibrosis across Organs Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Assistant – Immune Response (University of Cambridge) Research Technologist – Cell Separation (STEMCELL Technologies Inc.) Research Technologist – Cell Separation (STEMCELL Technologies Inc.) Postdoctoral Fellow – Immunotherapy (California Institute for Biomedical Research) Professorship – Molecular Immune Regulation (Kiel University) PhD Student – Cellular Immunotherapy (Glycostem Therapeutics) Postdoctoral Fellow – Immunoengineering for Muscle Regeneration (Duke University) Scientist/Senior Scientist – Lentivirus Production (Obsidian Therapeutics) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Human Immunology News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|